908 organization(s) found
IC–OS (International Cardio–Oncology Society)
The International Cardio-Oncology Society is committed to raising awareness about cardiovascular disease that commonly occurs in patients undergoing treatment for cancer. The ongoing success and complexity of current life-saving therapies has led to the recognition by healthcare providers, patients, and caregivers that cardiac health is vitally important in order to obtain the best patient outcomes. We aim to enhance recognition among providers that prevention and early detection of cardiovascular disease is essential to providing optimal protection for our patients.
ICPO (International Centers for Precision Oncology) Foundation
The International Centers for Precision Oncology (ICPO) Foundation is a nonprofit organization established in 2019 under German law by leading international medical practitioners and life sciences entrepreneurs. Cancer is one of the most significant health challenges of our time and the need for more effective treatments is pressing. Recognizing a paradigm shift in cancer care from one size fits all to a personalized approach, the ICPO Foundation´s aim is to gain momentum for Radiotheranostics in cancer care worldwide and scale global patient access to this innovative therapy. Radiomolecular Precision Oncology is a highly targeted therapy with low side effects, improved efficacy and patient outcomes. The ICPO Foundation is establishing an international collaborative network of accredited ICPO Theranostics Centers of Excellence by sharing knowledge, standards and education in Radiomolecular Precision Oncology.
ICR (The Institute of Cancer Research)
UK cancer research institute and partner of The Royal Marsden.
IDEAYA Biosciences
IDEAYA is a clinical-stage precision medicine oncology company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality � an emerging class of precision medicine targets.
IEO (European Institute of Oncology)
The IEO (European Institute of Oncology) is one of the world's most prestigious hospitals and the fastest growing comprehensive cancer centre in Europe. IEO integrates the various areas related to the fight against cancer such as prevention, diagnosis, treatment, training and education, basic and translational research. Mission & Values: The European Institute of Oncology (Istituto Europeo di Oncologia - IEO) strives for excellence in cancer prevention, early diagnosis and effective treatment. We aim to achieve this through clinical and scientific research development, organisational and management innovation, with a constant focus on the quality of the service provided to the patients.
IFM (Intergroupe Francophone du Myélome)
French-speaking cooperative group for clinical research on multiple myeloma.
Iksuda Therapeutics
The ADC field continues to grow as ongoing technology innovations address past shortcomings for an improved probability of success. Iksuda is at the forefront of this, developing class leading ADCs based on selecting the most clinically relevant combination of binder, conjugation chemistry, linker and payload mechanism. Our best-in-class clinical-stage ADCs validate the tumor-selective payload activation approach, which we continue to innovate. Our expanding early-stage ProAlk-ADC pipeline will offer new treatment choices for hard-to-treat cancers and help to address ADC sequencing � a major development challenge in the future.
Immatics
Since its foundation, Immatics has been relentlessly focused on building its scientific approach from the ground up to develop and deliver novel PRAME immunotherapies for patients with cancer. Today, Immatics is the global leader in the precision targeting of PRAME, a target expressed in more than 50 cancers, and has the broadest PRAME franchise with the most PRAME indications and modalities.
ImmunityBio
ImmunityBio is on a Mission: To continuously pursue new therapies that kill disease, not the immune system
Immunity for Health
A catalyst for public-private partnerships in vaccine related research and business.
Immunocore
We want to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.
Immunoneering
Powerful Science Engineered to Disrupt Cancer, Not Life For decades, most cancer treatments have used continuous inhibition, applying constant pressure to block tumor growth. While this can shrink tumors quickly, it gives cancer time to adapt and develop resistance. At Immuneering, we recognized the problem: predictable therapeutic pressure allows cancer to evolve. Our scientists developed Deep Cyclic Inhibitors, a new class of medicines designed to pulse faster than cancer�s adaptive mechanisms. This rhythmic approach disrupts the tumor�s ability to resist treatment while allowing healthy cells to recover between doses. The result is more durable tumor control and improved tolerability for patients.
Immuto Scientific
At Immuto Scientific, we are bridging the gap between biology and engineering to explore revolutionary new therapies for oncology. Founded by a pair of engineers, our approach is rooted in the belief that true breakthroughs come from building what doesn’t yet exist. We use radical-based protein labeling to unlock structural insights on the omic scale, challenging the status quo and transforming drug discovery.
IMS (International Myeloma Society)
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide. The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
INCA (Instituto Nacional de Câncer)
INCA is the body of the Ministry of Health responsible for the development and coordination of integrated actions in the prevention and control of cancer in Brazil. Those actions include hospital care provided directly and free of charge to cancer patients within Brazil's Unified Public Health System (SUS), and interventions in other strategic areas, such as prevention and early detection, training, research and epidemiological information. The Institute coordinates several national programs on cancer control and is equipped with the most modern public diagnostic imaging facility in Latin America.
INCa (l'Institut national du cancer)
In French: "L'Institut national du cancer (INCa) a pour ambition de jouer un rôle d’accélérateur de progrès, en apportant une vision intégrée de l’ensemble des dimensions sanitaire, scientifique, sociale, économique liées aux pathologies cancéreuses ainsi que des différents champs d’intervention (prévention, dépistage, soins, recherche). Ceci, au service des personnes malades, de leurs proches, des usagers du système de santé, de la population générale, des professionnels de santé, des chercheurs et des décideurs."
INCan (Instituto Nacional de Cancerología)
In Spanish: "El Instituto Nacional de Cancerología es un organismo descentralizado de tercer nivel, dependiente de la Secretaría de Salud; que brinda atención médica especializada a enfermos oncológicos siendo además un centro de referencia y órgano rector del cáncer en México. Dirige sus acciones a la atención de pacientes no derechohabientes de la seguridad social, provenientes de todo el país y ha sido política institucional, el otorgar servicios con eficiencia, calidad y calidez, con enfoque multidisciplinario en proceso diagnóstico, tratamiento, rehabilitación y seguimiento. Aunado a las funciones asistenciales como centro de enseñanza médica e investigación."
INC - Colombia (Instituto Nacional de Cancerología)
The National Cancer Institute (nstituto Nacional de Cancerología [INC], in Spanish) is the only State Entity at the national level, dedicated exclusively to the teaching, prevention, diagnosis, treatment, rehabilitation and intervention of cancer.
Incyclix Bio
Incyclix Bio is advancing next-generation precision treatments to regain control of the cell cycle where aberrant proliferation is a fundamental driver of many cancers. We believe the CDK family is a rich source of of novel cancer targets worthy of drug development. Our team is applying its unsurpassed expertise and deep knowledge of CDK inhibitors to bring hope to people with advanced and resistant cancers.ost cancer treatments have used continuous inhibition, applying constant pressure to block tumor growth. While this can shrink tumors quickly, it gives cancer time to adapt and develop resistance.
Indian Society of Hematology & Blood Transfusion
The Indian Society of Haematology and Blood Transfusion (ISHBT) is a non-governmental, not-for-profit professional membership organization established in 1959. The Society is dedicated to promoting excellence in patient care, research, and education in clinical and laboratory haematology. With a strong network of over 2,400 life members, ISHBT serves as a dynamic and inclusive platform for haematologists across India and beyond. It actively fosters academic advancement through its Annual National Conference, peripheral Continuing Medical Education (CME) programs, workshops, symposia, regular newsletters, and national scientific meetings that bring together leading experts and trainees from around the globe. ISHBT conducts quizzes for undergraduate, postgraduate, and postdoctoral students to foster interest in the field of haematology. The Society also awards various prizes, research grants, and medals to encourage academic excellence and stimulate research among young scholars.
INEN (Instituto Nacional de Enfermedades Neoplásicas)
In Spanish: “MISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como misión: "Proteger, promover, prevenir y garantizar la atención integral del paciente oncológico, dando prioridad a las personas de escasos recursos económicos; así como, controlar, técnica y administrativamente, a nivel nacional los servicios de salud de las enfermedades neoplásicas y realizar las actividades de investigación y docencia propias del Instituto”. VISIÓN: El Instituto Nacional de Enfermedades Neoplásicas (INEN), tiene como visión: “Perú libre de cáncer avanzado a través de nuestro liderazgo en políticas y acciones de excelencia que promuevan el acceso universal y equitativo a la prevención y control del cáncer”.”
InFocus Therapeutics
We have a novel discovery platform to identify differentiated RNA-targeting small molecules – faster.